Roche's Tecentriq (atezolizumab) Receives MHLW's Approval as the First Immunotherapy for Extensive-Stage Small Cell Lung Cancer in Japan
Shots:
- The approval is based on P-I/III IMpower133 study assessing Tecentriq (1200mg- IV-) + CT (carboplatin and etoposide) q3w over 60mins.- if tolerated subsequent infusion can be administered over 30mis. vs CT as monothx. in patients with extensive-stage small-cell lung cancer
- The P-I/III IMpower133 study results: median OS (12.3 vs 10.3mos.); m-PFS (5.2 vs 4.3mos.); safety profile was consistent with the previous study; no new safety signals is observed
- Tecentriq (atezolizumab) is a mAb targeting PD-L1- blocking its interaction with PD-1 and B7.1 receptor and becomes the new therapy option for patients with extensive-stage SCLC in 17yrs.
Click here to read full press release/ article
Ref: Chugai Pharmaceutical | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com